Synergistic activity of IDH1 inhibitor BAY1436032 with azacitidine in IDH1 mutant acute myeloid leukemia

Mutant isocitrate dehydrogenase 1 (mIDH1) inhibitors have shown single-agent activity in relapsed/refractory acute myeloid leukemia (AML), even though most patients eventually relapse. We evaluated the efficacy and molecular mechanism of the combination treatment with azacitidine, which is currently...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Haematologica
Päätekijät: Chaturvedi, Anuhar, Gupta, Charu, Gabdoulline, Razif, Borchert, Nora M., Goparaju, Ramya, Kaulfuss, Stefan, Gorlich, Kerstin, Schottmann, Renate, Othman, Basem, Welzenbach, Julia, Panknin, Olaf, Wagner, Markus, Geffers, Robert, Ganser, Arnold, Thol, Felicitas, Jeffers, Michael, Haegebarth, Andrea, Heuser, Michael
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Fondazione Ferrata Storti 2020
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7849562/
https://ncbi.nlm.nih.gov/pubmed/32241846
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2019.236992
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia